Circulating Angiopoietins-1 and -2, Angiopoietin Receptor Tie-2 and Vascular Endothelial Growth Factor-A as Biomarkers of Acute Myocardial Infarction: a Prospective Nested Case-Control Study by Iribarren, Carlos et al.
RESEARCH ARTICLE Open Access
Circulating Angiopoietins-1 and -2, Angiopoietin
Receptor Tie-2 and Vascular Endothelial Growth
Factor-A as Biomarkers of Acute Myocardial
Infarction: a Prospective Nested Case-Control
Study
Carlos Iribarren
1*, Bruce H Phelps
2, Jeanne A Darbinian
1, Edward R McCluskey
2, Charles P Quesenberry
1,
Evangelos Hytopoulos
2, Joseph H Vogelman
3 and Norman Orentreich
3
Abstract
Background: Angiogenesis is up-regulated in myocardial ischemia. However, limited data exist assessing the value
of circulating angiogenic biomarkers in predicting future incidence of acute myocardial infarction (AMI). Our aim
was to examine the association between circulating levels of markers of angiogenesis with risk of incident acute
myocardial infarction (AMI) in men and women.
Methods: We performed a case-control study (nested within a large cohort of persons receiving care within Kaiser
Permanente of Northern California) including 695 AMI cases and 690 controls individually matched on age, gender
and race/ethnicity.
Results: Median [inter-quartile range] serum concentrations of vascular endothelial growth factor-A (VEGF-A; 260
[252] vs. 235 [224] pg/mL; p = 0.01) and angiopoietin-2 (Ang-2; 1.18 [0.66] vs. 1.05 [0.58] ng/mL; p < 0.0001) were
significantly higher in AMI cases than in controls. By contrast, endothelium-specific receptor tyrosine kinase (Tie-2;
14.2 [3.7] vs. 14.0 [3.1] ng/mL; p = 0.07) and angiopoietin-1 levels (Ang-1; 33.1 [13.6] vs. 32.5 [12.7] ng/mL; p = 0.52)
did not differ significantly by case-control status. After adjustment for educational attainment, hypertension,
diabetes, smoking, alcohol consumption, body mass index, LDL-C, HDL-C, triglycerides and C-reactive protein, each
increment of 1 unit of Ang-2 as a Z score was associated with 1.17-fold (95 percent confidence interval, 1.02 to
1.35) increased odds of AMI, and the upper quartile of Ang-2, relative to the lowest quartile, was associated with
1.63-fold (95 percent confidence interval, 1.09 to 2.45) increased odds of AMI.
Conclusions: Our data support a role of Ang-2 as a biomarker of incident AMI independent of traditional risk factors.
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Background
Angiogenesis, the induction and growth of new blood
vessels from pre-existing ones, is a complex, highly
regulated system essential for embryonic development,
normal physiological growth, wound healing and tumor
progression [1,2]. In addition, it is now well-documented
that angiogenic factors are up-regulated (as a compensa-
tory mechanism to increase collateral circulation) in the
context of acute skeletal muscle [3] and myocardial
ischemia [4-6]. Atherosclerotic vessels often present
intra-plaque angiogenesis, a phenomenon that has been
hypothesized to contribute to progression and eventual
rupture of coronary artery lesions [7,8]. It is therefore
plausible that angiogenesis could exert both protective
and deleterious roles in development of coronary
disease.
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VEGF), the most extensively studied angiogenic factor,
is a heparin-binding homodimeric glycoprotein that
induces early endothelial cell migration, proliferation
and blood vessel formation [9,10]. Increased VEGF
mRNA and protein expression has been demonstrated
in ischemic human myocardium,
5 and plasma VEGF
levels have been shown to be increased in patients who
suffered an acute coronary syndrome (ACS) [11]. More-
over, VEGF was found to be a predictor of worse out-
come after ACS [12] and was, in the Pawtucket Heart
Health Program, a significant and independent predic-
tive factor of coronary heart disease (CHD) death [13].
More recently discovered regulators of angiogenesis are
the angiopoietins, which are the ligands of the endothe-
lium-specific receptor tyrosine kinase (Tie-2) [14,15].
Whereas angiopoetin-2 (Ang-2) destabilizes the vessel to
make it responsive to angiogenic growth factors such as
VEGF (i.e., functions as a ‘trigger’ of remodeling)
[16,17], angiopoietin-1 (Ang-1) promotes vascular stabi-
lization and counteracts VEGF-induced angiogenesis
[18]. In epidemiological studies, raised VEGF, Ang-2,
Tie-2 but not Ang-1 have been demonstrated in patients
after ACS.
11 In the only prior prospective study, Ang-2
but not Ang-1 was related to subsequent CVD events in
a sample of 251 hypertensive patients [19].
To date, no study has examined the value of VEGF
and the Angiopoietins/Tie-2 system as biomarkers of
acute myocardial infarction (AMI) risk in a large popu-
lation-based sample with measurement of these biomar-
kers in blood samples obtained before onset of AMI.
Our aim was therefore to: 1) examine the prospective
associations between circulating levels of VEGF, Ang-1,
Ang-2 and Tie-2 with risk of incident AMI in men and
women; 2) assess the degree of independence from tra-
ditional risk factors; and 3) test for, given the biological
synergistic and antagonistic interrelations between these
biomarkers, the six possible 2-way interactions, namely
V E G FXA n g - 1 ,V E G FXA n g - 2 ,V E G FXT i e - 2 ,A n g - 1
X Ang-2, Ang-1 X Tie-2 and Ang-2 X Tie-2.
Methods
Study Population and Design
We used a nested matched case-control study design.
The source population was a well-characterized, popula-
tion-based cohort of 83,772 persons receiving care
within Kaiser Permanente of Northern California, who
participated in the Multiphasic Health Checkup (MHC)
in the Oakland and San Francisco medical centers
between 1984 and 1992. The MHC consisted of an
innovative system of regular and comprehensive, broad-
spectrum physical examinations, including routine blood
testing and urinalysis, with the goal of providing health
maintenance through early diagnosis [13,20-22].
Examinees were instructed not to have any food, coffee,
tea or alcohol for at least four hours before the MHC
appointment. At the exam, several tubes of blood were
drawn and the blood was allowed to clot and then was
centrifuged to separate the serum (liquid) portion from
the blood cell portion. A 2 mL sample of the serum was
taken and labeled, showing the sample’s identification
number, donor’s sex, date of birth, and date of blood
sampling. From this large cohort, we selected 695 inci-
dent AMI cases and we implemented incidence density
sampling [23] to select 1:1 (n = 695) age-, gender-, and
race-matched controls who remained free of AMI up to
the date when the paired subject suffered the AMI. The
incident density sampling scheme resulted in 5 controls
being selected twice (stated differently, 5 AMI cases
shared their respective controls with 5 other AMI cases).
Kaiser Permanente of Northern California is a large,
integrated healthcare delivery system that provides care
for about one-third of the insured adult population in
the greater San Francisco Bay Area. Kaiser members are
representative of the demographic and clinical charac-
teristics of the surrounding local and state population
with the exception of the low and high segments of the
income distribution [24]. The AMI cases were identified
from electronic computerized hospitalization records
during the first 10 years of follow up, with the require-
ment that AMI (ICD-9 code 410) be listed as principal
discharge diagnosis or underlying cause death and were
required to have no history of prior AMI. The strategy
for inclusion of events included all AMIs that occurred
in the first 5 years (n = 416) plus a random selection of
279 AMI that occurred between 5 and 10 years after the
MHC. This ascertainment method has been shown to
have 96% specificity based on modified World Health
Organization criteria of at least 2 of 3 present of: (a)
ischemic symptoms, (b) ECG changes, or (c) enzyme or
pathological evidence of infarction, using chart review
and laboratory data as “gold standard” data sources in a
prior Kaiser Permanente study [25]. The mean ± SD
time between MHC and AMI was 5.2 ± 2.9 years (mini-
mum, < 1 year; maximum, 10 years). The Kaiser Foun-
dation Institutional Review Board approved the study
protocol. VEGF and Ang-2 were measured in all AMI
cases and controls. For budgetary constraints, Ang-1
and Tie-2 were measured in a 50% random sample of
AMI cases and controls (in 318 case-control pairs).
Laboratory Methods
At the MHC, serum samples were packed in dry ice in
boxes of 100 and shipped overnight to the Orentreich
Foundation for the Advancement of Science (OFAS),
Inc., Cold Spring-on-Hudson, N.Y., where they have
been computer-cataloged and maintained at -40 degrees
Celsius. Aliquots of serum from the study subjects were
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overnight in dry ice to Aviir, Inc., whose personnel
remained blinded as to case-control status. A second ali-
quot was given to the Advanced Clinical Laboratory at
OFAS for lipid and C-reactive protein (CRP) testing.
Concentrations of VEGF and Ang-2 were measured
using a LUMINEX xMAP™ Multiplex Assay, custom
developed by R&D Systems (Minneapolis, MN) to mea-
sure the concentrations of 16 low abundant serum pro-
teins. The limit of detection (LOD) for VEGF was 6 pg/
ml, with an intra-assay coefficient of variation (CV) of
6% and an inter-assay CV of 8%. The LOD for Ang-2
was 6 pg/ml, with an intra-assay CV of 6% and an inter-
assay CV of 7%. Concentrations of Ang-1 and Tie-2
were measured using Quantikine ELISA reagent kits and
controls for each protein biomarker from R&D Systems
(Minneapolis, MN, Cat # DANG10 and DTE200, respec-
tively). HDL-C, LDL-C and triglycerides were measured
on the Beckman Instruments Inc. (Brea, CA) Synchron
Clinical System CX5. The CV of these measurements
were less than 4.5% for HDL-C and triglycerides and
less than 3% for LDL-C. CRP was measured on Siemens
Health Care Diagnostics (Deerfield. IL) Immulite 1000,
and the CV was less than 7%.
Covariates
Race\ethnicity was classified as white, black, Hispanic/
Latino, Asian and other by self-report. Education level
was categorized as high school graduate or less, some
college, and college graduate or higher. Cigarette smok-
ing status was classified as never, former, and current.
Subjects were classified according to alcohol intake (in
the past year) as abstainers and consumers of < 1 drink
per day (i.e., occasional), 1-2 drinks per day or 3 or
more drinks per day. Height and weight were measured
using standardized methods and body mass index esti-
mated as weight in kg divided by height in m
2. Systolic
and diastolic blood pressures (one reading) were
obtained in supine position with a standard manual cuff.
Hypertension was defined as systolic blood pressure ≥
140 mmHg and diastolic blood pressure ≥ 90 mmHg or
use of antihypertensive medication. Diabetes mellitus
was defined as self-report of a physician diagnosis or
use of diabetes medications (insulin or oral hypoglyce-
mic agents). We estimated the 10-year Framingham
Risk Score for each subject as originally described [26].
Statistical Analysis
Case-control differences were ascertained using the t-
test for continuous (normally distributed) variables and
the Chi-Square test for categorical variables. Because of
skewness, univariate case-control differences for trigly-
cerides, CRP and the 4 angiogenic factors were ascer-
tained using the Wilcoxon two-sample test. To assess
independent correlates of each angiogenic factors, we
employed multiple linear regression with forward entry
of covariates (p-stay in the model = 0.05) and forcing in
a categorical variable for case-control status. Conditional
logistic regression was then applied to quantify the rela-
tive odds of being an AMI case associated with 1 SD
linear increment in each of the angiogenic factors. To
allow comparability of effects, each angiogenic factor
was log10-transformed and then scaled as a Z score by
subtracting its mean and dividing by its standard devia-
tion (SD); both means and SDs were estimated among
controls. Two sequential models were fitted: first, a
model without any covariates (age, sex and race adjusted
for by design), and second, a model adjusting for educa-
tion attainment, alcohol consumption, cigarette smok-
ing, diabetes, hypertension, body mass index, LDL-C,
HDL-C, triglycerides and CRP. We formally tested, in
separate minimally-adjusted models, for all possible 2-
way interactions (n = 6) between angiogenic factors as
continuous variables. Because of prior research demon-
strating that Ang-2 was predictive of CVD events in
patients with hypertension [19], we also ran uncondi-
tional logistic models stratifying by hypertension status
and formally tested the interaction between Ang-2 as a
continuous variable and hypertension in both mini-
mally-and fully-adjusted models. Finally, we ascertained
strength of association as a function of time by fitting
two separate conditional logistic models, one for AMI
cases that occurred in the first 5 years post MHC and a
second for AMI cases in years 6 to 10 post MHC. The
SAS software, version 9 (SAS Institute, Cary, NC), was
used in all statistical analyses.
Results
Both AMI cases and controls were, on average, 62 years
old at the MHC (Table 1); about 38 percent in each
group were female, 54 percent white, 34 percent black,
6 percent Hispanic/Latino and 6 percent Asian. Educa-
tional attainment was lower in cases than in controls
and current smoking was more prevalent in cases than
in controls. Relative to controls, AMI cases tended to
r e p o r tl e s sc o n s u m p t i o no f1 - 2a n do f3o rm o r ea l c o -
holic drinks per day. As expected, a positive history of
hypertension and diabetes was more frequent among
cases. Mean or median BMI, triglycerides, LDL-C and
CRP were higher whereas HDL-C levels were lower in
cases than in controls. Based on the 10-year FRS risk
calculation, 38 percent of cases and 31 of controls were
at intermediate risk, whereas 30 percent of cases and 11
percent of controls were at high risk. Levels and distri-
bution of characteristics (and the case-control patterns)
were similar in the 50 percent random sample where
Ang-1 and Tie-2 were measured (data not shown). Con-
centrations of VEGF and Ang-2 were significantly higher
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Page 3 of 9Table 1 Baseline characteristics of AMI cases and controls, Kaiser Permanente Multiphasic Health Checkup, 1984-1992.
AMI Cases
(n = 695)
Controls
(n = 690)
p-value
N (%) or Mean ± SD
Characteristics
Age, years* 62 ± 11 62 ± 11
Gender*
Men 432 (62.2) 430 (62.3)
Women 263 (37.8) 260 (37.7)
Race/ethnicity*
White 377 (54.2) 373 (54.1)
Black 235 (33.8) 234 (33.9)
Asian 39 (5.6) 39 (5.7)
Latino 41 (5.9) 41 (5.9)
Other 3 (0.4) 3 (0.4)
Education level < 0.0001
High school graduate or less 343 (49.4) 268 (38.8)
Some college 202 (29.1) 198 (28.7)
College graduate or higher 150 (21.6) 224 (32.5)
Cigarette smoking status < 0.0001
Never 289 (41.6) 336 (48.7)
Former 200 (28.8) 218 (31.6)
Current 206 (29.6) 136 (19.7)
Alcohol consumption < 0.0001
Abstainer 79 (11.4) 45 (6.5)
Occasional 365 (52.5) 348 (50.4)
1-2 drinks/day 205 (29.5) 239 (34.6)
≥ 3 drinks/day 46 (6.6) 58 (8.4)
Hypertension 531 (76.4) 417 (60.4) < 0.0001
Diabetes 147 (21.2) 49 (7.1) < 0.0001
Body mass index, Kg/m
2 27.4 ± 4.9 26.6 ± 4.7 0.002
Serum Triglycerides (mmol/L)† 1.80 (1.33) 1.38 (1.08) < 0.0001
Serum HDL Cholesterol (mmol/L) 1.11 ± 0.34 1.27 ± 0.39 < 0.0001
Serum LDL Cholesterol (mmol/L) 2.90 ± 0.75 2.59 ± 0.72 < 0.0001
C-reactive protein (mg/L) † 2.52 (4.37) 1.55 (2.80) < 0.0001
10-year Framingham Risk Score < 0.0001
Low (< 10%) 219 (31.5) 399 (57.8)
Intermediate (10- < 20%) 265 (38.1) 212 (30.7)
High (≥ 20%) 211 (30.4) 79 (11.4)
Angiopoietin-1 (ng/ml) †‡ 33.1 (13.6) 32.5 (12.7) 0.52
Angiopoietin-2 (ng/ml) † 1.18 (0.66) 1.05 (0.58) < 0.0001
Tie-2 (ng/ml) †‡ 14.2 (3.7) 14.0 (3.1) 0.07
Vascular Endothelial Growth Factor-A (pg/ml) † 260 (252) 235 (224) 0.01
* Matching factors; † Median (Interquartile range); ‡ measured in a 50% random sample
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differences existed for Ang-1 and Tie-2 (Figure 1).
Table 2 summarizes the bivariate correlations amongst
continuous variables. The highest correlation was noted
between triglycerides and HDL-C (r = -0.55). The correla-
tions between the four angiogenic factors were weak (r =
0.14 or lower), and the correlations between CRP and
angiogenic factors were also weak ranging from 0.22 for
Ang-2 and 0.16 for Ang-1. The independent correlates of
VEGF, accounting for 6 percent of its variance were CRP,
hypertension, less than a high school education, current
smoking and triglycerides (Table 3). The factors indepen-
dently related to Ang-2 were CRP, diabetes, current
smoking, male gender, BMI, age, consumption of 3 or
more alcoholic drinks per day, LDL-C and HDL-C,
accounting for 18 percent of its variance (Table 3). CRP,
LDL-C, male gender and occasional alcohol consumption
were the independent predictors of Ang-1, accounting for
6 percent of its variance (Table 3). In turn, the indepen-
dent covariables of Tie-2 were diabetes, HDL-C, CRP and
triglycerides, and these variables accounted for 12 percent
of the variation in Tie-2 levels (Table 3). Results of the
conditional logistic regression analysis are presented in
Table 4. In the minimally adjusted model, there were sig-
nificantly increased odds of AMI associated with linear
increases in VEGF, Ang-2 and Tie-2, and no association
Figure 1 Box plots of Angiopoietin-1, Angiopoietin-2, Tie-2, and Vascular Endothelial Growth Factor-A, by Case-Control Status
showing minimum, 25th, 50th (horizontal bar), mean (dot), 75th percentile and maximum.
Table 2 Spearman correlations* amongst continuous variables (n = 1,380).
VEGF-A Ang-2 Ang-1† Tie-2† CRP LDL HDL Triglycerides Age BMI
VEGF-A 1.00 0.11 0.31 0.06 0.19 0.02 -0.06 0.09 -0.01 0.07
Ang-2 1.00 -0.04 0.14 0.22 -0.03 -0.05 0.07 0.09 0.19
Ang-1† 1.00 0.01 0.16 0.14 0.06 0.06 0.04 -0.003
Tie-2† 1.00 0.20 0.04 -0.19 0.16 -0.05 0.11
CRP 1.00 0.09 -0.17 0.20 0.02 0.38
LDL 1.00 0.03 0.28 0.01 0.04
HDL 1.00 -0.55 0.13 -0.23
Triglycerides 1.00 -0.001 0.25
Age 1.00 -0.11
BMI 1.00
* Controlling for case-control status; † measured in a 50% random sample (n = 634)
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Ang-2, lower for VEGF and intermediate for Tie-2. After
adjustments for educational attainment, hypertension, dia-
betes, smoking, alcohol consumption, BMI, LDL-C, HDL-
C, triglycerides and CRP, the association between VEGF
and AMI was attenuated and became non-statistically sig-
nificant. The association between Ang-2 and AMI was
also attenuated after multivariate adjustment but remained
statistically significant. A noteworthy finding was that a
linear increment of Tie-2 became significantly associated
with decreased odds of AMI after adjustment for all study
covariates. An additional fully-adjusted model entering
categorical variables for quartiles of Ang-2 (cut-points
defined among controls), quartiles 2, 3 and 4, relative to
quartile 1, were associated with 1.25 (95% CI, 0.85 to
1.84), 1.38 (95% CI, 0.93 to 2.04) and 1.63 (95% CI, 1.09 to
2.45) increased odds of AMI, respectively. In fully-adjusted
conditional logistic models stratified by years to AMI, the
OR associated with 1 SD increment of Ang-2 (as a Z
score) were 1.16 (95% CI, 0.96 to 1.41) and 1.21 (95% CI,
0.97 to 1.51) during the first 5 years and during years 6 to
10, respectively.
In six separate minimally-adjusted models, each
including main and interactive effects for the two angio-
genic factors considered, no evidence was found of sig-
nificant 2-way interactions (all p-values ≥ 0.09). When
the sample of AMI cases and controls was divided into
6 groups according to low, intermediate and high 10-
year Framingham risk crossed with low/high Ang-2
(defining low Ang-2 as quartiles 1 through 3 and high
Ang-2 as quartile 4 and considering low FRS/low Ang-2
as referent), a consistent pattern emerged such that in
each FRS category there was a gradient of increased
adjusted odds of AMI moving from low to high Ang-2
(Figure 2). However, the confidence intervals overlapped
in each of the three FRS levels, and thus there were no
statistical significant differences in adjusted odds of
AMI comparing low vs. high Ang-2 within each of the
FRS categories. In minimally-adjusted unmatched logis-
tic regression stratified by hypertension status, each
increment of Ang-2 (1 unit of its Z score) was asso-
ciated with 1.16 (95% CI, 0.95 to 1.42) increased odds of
AMI among those without hypertension and with 1.30
(95% CI, 1.13 to 1.48) increased odds of AMI among
those with hypertension. These OR estimates were 1.04
(95% CI, 0.83 to 1.31) and 1.12 (0.96 to 1.31), respec-
tively, after full multivariate adjustment within hyperten-
sion strata. The p-values for Ang-2 by hypertension
interaction were 0.47 in the minimally-adjusted model
and 0.54 in the fully-adjusted model.
Discussion
Angiogenesis is essential for the repair of wounds and
tissues damaged by ischemia (and for the process
whereby collateral circulation develops in the context of
ischemia), but it also may enhance neovascularization-
dependent disease such as tumor or atherosclerotic pla-
que [4-8]. In this population-based case-control study,
elevated levels of Ang-2 were significantly and indepen-
dently related to future likelihood of AMI, which is con-
sistent with the notion that an angiogenic compensatory
Table 3 Independent predictors of angiogenic factors.
Angiogenic Factor b SE p Model
R
2
VEGF-A (pg/mL)*
Log CRP/SD 39.4 6.0 < 0.0001 0.040
Hypertension 30.3 13.1 < 0.0001 0.046
High school graduate or less -30.3 14.8 0.04 0.051
Current smoking 39.8 15.1 0.008 0.057
Log triglycerides/SD 12.6 6.0 0.03 0.059
Ang-2 (ng/mL)*
Log CRP/SD 0.061 0.016 < 0.0001 0.06
Diabetes 0.244 0.043 < 0.0001 0.09
Current smoking 0.278 0.038 < 0.0001 0.12
Male gender -0.17 0.034 < 0.0001 0.13
BMI/SD 0.071 0.016 < 0.0001 0.15
Age/10 years 0.069 0.015 < 0.0001 0.16
Alcohol consumption ≥ 3 drinks/
day
0.222 0.059 0.0002 0.17
Ang-1 (ng/mL)†
Log CRP/SD 1.16 0.37 0.002 0.02
LDL/SD 1.01 0.38 0.008 0.03
Male gender -2.14 0.83 0.009 0.04
Occasional alcohol consumption -2.85 0.89 0.001 0.06
Tie-2 (ng/mL)†
Diabetes 1.91 0.32 < 0.0001 0.07
HDL/SD -0.48 0.12 < 0.0001 0.10
Log CRP/SD 0.36 0.11 < 0.0001 0.11
Log triglycerides/SD 0.25 0.13 0.05 0.12
* n = 1,380; controlling for case-control status
† n = 630; controlling for case-control status
Table 4 Unadjusted and adjusted odds ratios and 95
percent confidence intervals of acute myocardial
infarction from 4 separate models.
Angiogenic factors Minimally-adjusted* Adjusted†
VEGF-A, 1 unit of Z score 1.13 (1.02-1.26) 1.01 (0.89-1.15)
Ang-2, 1 unit of Z score 1.31 (1.17-1.46) 1.17 (1.02-1.35)
Ang-1, 1 unit of Z score 0.98 (0.84-1.13) 0.95 (0.78-1.15)
Tie-2, 1 unit of Z score 1.19 (1.01-1.40) 0.79 (0.63-0.98)
* Adjusted for matching factors (age, gender, race/ethnicity) by design
† additional adjustment for diabetes, hypertension, smoking, alcohol
consumption, BMI, LDL, HDL, triglycerides and CRP
using a 50% random sample
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may exist even years before the clinical presentation of
AMI. Two other angiogenic factors, VEGF and Tie-2
were also associated with increased future odds of AMI
in minimally-adjusted analyses, but their respective asso-
ciation became null and protective, respectively, after
multivariable adjustment for traditional risk factors and
CRP.
In disagreement with our findings, a prior population-
based prospective study reported that baseline levels of
VEGF-A were significantly and independently associated
with the risk of CHD death [13]. There are some differ-
ences between that study and ours that may explain this
discrepancy in results. First the Eaton et al. study was a
case-cohort design whereas ours was a case-control
matched design. Second, the Eaton et al study focused
on fatal CHD, while our endpoint was both non-fatal or
fatal AMI. Unlike Eaton et al., we measured and
adjusted for CRP in the multivariable model (CRP and
VEGF correlated 0.19 in our sample). Lastly, the study
sample in Eaton et al. was 92% white, while our samples
of AMI cases and matched controls were 54% white.
Our null (albeit observational) results for VEGF fit
with the current evidence from rigorous phase II and III
clinical trials of VEGF gene therapy demonstrating no
benefit [27]. A new promising paradigm for therapeutic
angiogenesis is emerging that incorporates multiple
growth factors and “master switch” agents [28,29].
The fact that Tie-2 had a positive association in the
minimally-adjusted model that became protective in the
multivariate context is somewhat perplexing and
deserves some comment. In sensitivity analysis adding
o n ec o v a r i a t ea tat i m e ,t h el a r g e s ta t t e n u a t i o na n d
reversal of directionality of association was apparent
with the inclusion of HDL-C, which was one of the
strongest covariates of Tie-2. This finding warrants
further research in other populations and locations.
Our findings also suggest that the predictive ability of
Ang-2 did not vary with years to event (similar effects
were seen regardless of whether the AMI had occurred
in the first 5 years of follow-up or in the subsequent 6-
10 years of follow-up). We found a trend toward a
stronger Ang-2-AMI association among those with
hypertension (compared to those without hypertension)
but failed to demonstrate a significant interaction
between these two factors. Our results among hyperten-
sive participants are in agreement with a study in the
UK concluding that raised levels of Ang-2 were predic-
tive of AMI among 251 patients with hypertension [19].
The strengths of our study include the availability of
serum samples many years before the development of
AMI in case subjects. Another strength is the ethnic
diversity of the AMI cases and controls. Our study has a
number of limitations that should be appreciated. First,
a legitimate concern is protein degradation as a result of
the advanced age and conditions of storage of the serum
samples. This is not likely to have biased our results
since the mean (SD) concentrations of VEGF in our
controls (295 [235] pg/ml) is similar to the mean (SD)
levels reported by Eaton et al. for the entire sub-cohort
(303 [219] pg/ml) [13]. In addition, to specifically
address the integrity of the serum bank, OFAS measured
the level of dehydroepiandrosterone sulfate (DHEAS), a
common hormone that declines over the life span, in
Figure 2 Combined Effect of 10-year Framingham Risk and Ang-2 on Odds Ratio of AMI. Low Ang-2 (light pattern) defined as quartiles 1
through 3; high Ang-2 (heavy pattern) defined as quartile 4.
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ferent age groups. Levels of DHEAS in the 517 long-fro-
zen sera correlated extremely well with levels of DHEAS
in the 2,500 unfrozen clinical samples, and this excellent
correlation established that the chemical integrity of the
serum had been maintained over the years. Additional
protein studies using this serum bank have also con-
firmed the chemical integrity of the samples [28]. More-
over, to determine if desiccation had occurred, the
serum concentration of sodium was measured in each
specimen with a Beckman model E2A analyzer (Irvine,
CA) and none of our samples were outside the physiolo-
gical normal range of 135-153 mmol/L. Another limita-
tion of our study is that we did not have measures of
other angiogenic factors such as bFGF (basic fibroblast
growth factor) [30], endostatin [31] or angiostatin [32],
thought to play important roles in collateral vessel for-
mation and plaque angiogenesis. A third (methodologi-
cal) limitation is that our matched design precluded
estimation of incremental discrimination by ROC analy-
sis or the net reclassification improvement [33] after
considering Ang-2. This is because estimation of asso-
ciation is via conditional logistic regression, appropriate
to the nested case-control study design, which does not
provide estimates of the intercepts. Finally, we did not
have information on medical or surgical management of
the AMI cases, although the likelihood of these inter-
ventions affecting the measurement of angiogenic fac-
tors is very low because the samples utilized antedated
the event up to 10 years and were obtained when the
patients were asymptomatic.
Conclusions
This study provides further evidence supporting a role
of biomarkers of angiogenesis in the prediction of AMI.
In particular, Ang-2 emerged as a particularly promising
biomarker. These findings should motivate additional
research to elucidate the usefulness of Ang-2 in CVD
risk stratification either alone or as part of multiple bio-
marker approaches.
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